A major expansion of NHS weight loss treatment begins today, as GPS in England Now are able to determine the mounjaro – An injected drug that is also first known as Tirzepetide.
Once limited to expert clinics or private prescriptions, Maunjaro will now be accessible through general practice for people with severe obese, in particular, more than 40 BMIs and at least four related health conditions, such as type 2 diabetes, heart disease, or sleep apnea.
This step is part of a broad rollout aimed at reaching around 220,000 people over the next three years.
Supporters see this as a success in dealing with the disease related to obesity and reducing long -term pressure on NHS. But others, including major GP and pharmacy experts, have warned of potential downside – to increase the charge and fear the demands of training will be seen as a quick improvement without the support of the appropriate lifestyle.
“There is no silver bullet,” said Professor Kamila Hothorn, Chairman of the Royal College of GPS. He said, “We also need to focus on prevention, people are gaining overweight in the first place so that they do not need medical intervention later,” he said.
As NHS has started this major initiative, we want to know what you think: What are the weight loss medicines when widely available on NHS? Or should they be reserved only for the most severe cases?
Vote in our pole and share your thoughts Comments below.
